Could biosensors and smart dressings be the final frontier in wound diagnostics? SmartTRAK explores the current progress of this market and how it could develop.

It has been 15 years since the World Union of Wound Healing Societies’ Initiative published a consensus document entitled “Diagnostics and Wounds.” Since then, the clinical practice around assessing and diagnosing wounds has not evolved at the same rate as that of treatments. At the same time, the need for improved wound diagnostics has never been greater given burgeoning chronic wound numbers and the continued shift of wound care services to the outpatient setting.

Could the next area of development be that of biosensors and smart dressings? SmartTRAK believes there is increasing evidence that this could be the case. In this article, we explore the developments that are taking place, how the identification of infection biomarkers may be lucrative and ways the market may change in the coming years.

Among the many topics discussed in this article are:

Despite mixed results from Trauma players, the segment experienced healthy growth as mergers and acquisitions were plentiful and regulatory clearances show promise of future new product introductions.

In June, wound, ostomy and continence-focused nurses, and supporting industry gathered in Fort Worth, TX for the hybrid WOCNext 2022 conference. In-person attendance was below expectations, but healthy booth time allowed for product discussions with exhibitors.

Improved aspiration systems, large-bore catheters, balloon-guide catheters and radial access top the list of neurovascular device trends that will continue in 2022.

In the market for mechanical thrombectomy devices, the pace of innovation shows no signs of slowing down in 2022. Manufacturers are designing neurointerventional devices with an eye toward improving first-pass effect, recanalization rates and reducing procedure times to ultimately improve patient outcomes In this article, SmartTRAK highlights recent trends in neurovascular technologies, including variable pressure aspiration systems, large-bore catheters (LBCs), balloon-guide catheters (BGCs) and radial access, as key areas of innovation moving into 2022.

Along with the recent trends in neurovascular technologies, the following topics are covered in detail in this article, which is available for download here:

• Outgrowing Standard Aspiration Systems
• Continued Trend Toward Large-Bore Catheters for Access and Aspiration
• New Designs and Applications for Balloon-Guide Catheters
• Increasing Competition in Radial Access

• See gaps in your product portfolio vs your competitors’ 
• Discover your next acquisition candidate
• Find a distribution partner

…in just a few clicks!

BE THE EXPERT who fills in the gaps in your company's portfolio! Read on to view a "How To" video and learn how to outperform your peers and competitors by saving yourself HOURS of research with just ONE search.

That’s the power of SmartTRAK!

For example…

Q122 started slow but ended on a bright note as COVID-19 concerns faded and surgical volumes approached pre-pandemic levels.

Virtually all orthopedic/spine companies experienced the same pattern with elective procedures during the quarter. In general, elective procedure case counts were pressured in January through the beginning of February as a surge in COVID-19 cases impacted patients and contributed to staffing shortages at healthcare facilities. However, by the end of the quarter elective procedures approached or returned to pre-COVID levels.

Among the many topics covered in detail in our comprehensive Q122 OrthoBio Market Recap* are:

Wallaby Medical CEO and founder Michael Alper discusses the Company’s recent acquisition of phenox GmBH and positioning the Company for success in an interview with SmartTRAK

With no overlap from a product or geographic perspective, Wallaby Medical’s recent acquisition of phenox GmBH was a “match made in heaven” according to Wallaby’s CEO and founder Michael Alper. In an interview with SmartTRAK, Alper discusses the acquisition, company synergies, complementary channels and the Company’s strategies for global expansion and becoming a leader in the market for neurovascular intervention.

To find out more, including details about the acquisition, the Company and its key products and markets, click on the following video to listen to the interview recorded via Zoom (21:07 min). A link to download the complete transcript of the interview is also provided below.

For Q122, US Joint Fluid Replacement market players continued on a running growth, which did not seem too disrupted by the COVID Omicron variant. Furthermore, some players shared that despite physicians’ offices not yet running at 100% levels, company sales representatives were able to hold face-to-face visits and secure new orders.

Rafael Carbunaru, PhD, Boston Scientific’s VP of R&D, discusses DBS therapy and STIMVIEW XT, the Company’s new advanced visualization software for DBS programming, in an in-depth interview with SmartTRAK at INS 2022

Rafael Carbunaru, PhD, vice president of research and development for Boston Scientific (BSX), discusses deep brain stimulation (DBS) and STIMVIEW XT, the Company’s new advanced visualization software for DBS programming in an in-depth interview with SmartTRAK at the International Neuromodulation Society (INS) World Congress in Barcelona, Spain held May 21-26.

Used with the Vercise Genus DBS portfolio and developed in collaboration with Brainlab, STIMVIEW XT uses patient-specific 3D visualization of patient anatomy and enables clinicians to see, shape and steer DBS therapy using point-and-click interface designed to simplify programming, save time and better personalize therapy.

To find out more about STIMVIEW XT, DBS workflows and BSX’s vision for DBS, click on the following video to listen to the interview recorded live at INS 2022 (45:16 min). For more details, interview topics by timecode are provided below. A link to download a complete transcript of the interview is also available below.

SmartTRAK reports that challenging conditions lead to minimal innovation in Paris.

It was third time lucky for the approximately 3,500 attendees of the 2022 European Wound Management Association (EWMA) conference in Paris. Although not yet back to a pre-pandemic number of participants, it was encouraging to see an international presence without the barrier of COVID-19 restrictions. Previous dates in 2020 and early 2022 fell to the pandemic, so great credit goes to the organizers and exhibitors for persevering and delivering a positive and engaging event.

Among the many topics covered in this SmartTRAK perspective article, which you can download here, are:

• MDR Consuming R&D Resources
• Clouds over Germany - Is There a Silver Lining?
• Establishing a European Foothold
• The Trend in Using Fewer Layers in Compress